Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Dropped 18.2% in First Three Quarters of 2022

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 191.5 million yuan in the first three quarters of 2022, down 18.2% year-on-year.

Meanwhile, the company posted 7.3 billion yuan in revenue, up 0.3% year-on-year.

At the end of the reporting period, it had 7.4 billion yuan in total assets and 5 billion yuan in total liabilities, with a liability-to-asset ratio of 67.8%.